Y-mAbs Therapeutics, Inc. Forecast, price target & analysts
Y-mAbs Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Y-mAbs Therapeutics, Inc. Classifications & Recommendation:
Y-mAbs Therapeutics, Inc. Price Target
| Target Price | $19.85 |
| Price | $5.42 |
| Potential |
266.17%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Y-mAbs Therapeutics, Inc. 2026 .
The average Y-mAbs Therapeutics, Inc. target price is $19.85.
This is
266.17%
register free of charge
$26.00
379.70%
register free of charge
$11.00
102.95%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Y-mAbs Therapeutics, Inc. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Y-mAbs Therapeutics, Inc. stock has an average upside potential 2026 of
266.17%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 84.82 | 88.20 |
| 29.95% | 3.99% | |
| EBITDA Margin | -24.12% | -37.14% |
| 83.25% | 53.97% | |
| Net Margin | -25.86% | -31.42% |
| 82.78% | 21.48% |
13 Analysts have issued a sales forecast Y-mAbs Therapeutics, Inc. 2024 . The average Y-mAbs Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Y-mAbs Therapeutics, Inc. EBITDA forecast 2024. The average Y-mAbs Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Y-mAbs Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average Y-mAbs Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.49 | -0.62 |
| 77.63% | 26.53% | |
| P/E | negative | |
| EV/Sales | 1.99 |
12 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast for earnings per share. The average Y-mAbs Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Y-mAbs Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Y-mAbs Therapeutics, Inc....
Current Y-mAbs Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 13 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 11 2024 |
| Brookline Capital | Locked ➜ Locked | Locked | Dec 05 2024 |
| Oppenheimer | Locked ➜ Locked | Locked | Nov 18 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 15 2024 |
| Wedbush | Locked ➜ Locked | Locked | Sep 10 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Sep 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 11 2024 |
|
Locked
Brookline Capital: Locked ➜ Locked
|
Dec 05 2024 |
|
Locked
Oppenheimer: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 15 2024 |
|
Locked
Wedbush: Locked ➜ Locked
|
Sep 10 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Sep 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
